Cite
HARVARD Citation
Cousin, S. et al. (2022). Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study. International journal of cancer. 150 (6), pp. 993-1006. [Online].